Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5004650 | 0.87 | PTPN1 (0.42) | PTPN1KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| Bromide SCHEMBL3845607 | 0.87 | PTPN1 (0.42) | PTPN1KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| Bromide SCHEMBL3851561 | 0.86 | MAPT (0.50) | KDM4ESMN1; SMN2ALDH1A1HTTNPC1 | |
| SCHEMBL6535470 | 0.85 | PTPN1 (0.43) | PTPN1KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| Bromide SCHEMBL2954276 | 0.85 | ALDH1A1 (0.48) | PTPN1KDM4ESMN1; SMN2ALDH1A1HTT | |
| SCHEMBL6938200 | 0.84 | ALDH1A1 (0.49) | KDM4ESMN1; SMN2ALDH1A1HTTNPC1 | |
| SCHEMBL1820216 | 0.84 | ALDH1A1 (0.46) | PTPN1KDM4ESMN1; SMN2ALDH1A1HTT | |
| Bromide SCHEMBL3845606 | 0.83 | ALDH1A1 (0.60) | KDM4EALDH1A1HTTNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL33828 | 0.82 | RAB9A (0.46) | PTPN1KDM4ESMN1; SMN2ALDH1A1HTT | |
| Bromide SCHEMBL3843810 | 0.81 | HTR2A (0.43) | KDM4ESMN1; SMN2HTR2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1353669-B1 | METHOD FOR TREATING GLAUCOMA | ALTEON INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1305024-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | disclosed |
| EP-1305024-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | Alteon, Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002007725-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | PTPN1 3978/4885KDM4E 3755/4885SMN1; SMN2 605/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | PTPN1 4787/4885KDM4E 4361/4885SMN1; SMN2 3940/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | PTPN1 3830/4885KDM4E 3863/4885SMN1; SMN2 549/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | PTPN1 4026/4885KDM4E 3627/4885SMN1; SMN2 1693/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | PTPN1 3887/4885KDM4E 3355/4885SMN1; SMN2 295/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | PTPN1 4599/4885KDM4E 4392/4885SMN1; SMN2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.